Intermittent 2-Hour-Infusion of Cladribine as First-Line Therapy or in First Relapse of Progressive Advanced Low-Grade and Mantle Cell Lymphomas-Reference-Cited by-同舟云学术

Intermittent 2-Hour-Infusion of Cladribine as First-Line Therapy or in First Relapse of Progressive Advanced Low-Grade and Mantle Cell Lymphomas

Published:1999-01 Issue:1-2 Volume:35 Page:129-138
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Rummel Mathias J.¹,Chow Kai U.¹,Jäger Elke²,Leimer Lothar³,Hossfeld Deter K.⁴,Bergmann Lothar⁵,Peters Hans D.⁶,Hansmann Martin L.⁷,Meyer Annette¹,Hoelzer Dieter¹,Mitrou Paris S.¹

Affiliation:

1. Med. Klinik III, Johann Wolfgang Goethe-Universitäarsklinik, Frankfurt/Main

2. II. Med Klinik, Krankenhaus Nordwest, Frankfurt/Main

3. Hamatologie/Onkologie. Roberr-Bosch-Krankenhaus, Stuttgart

4. Hämatologie/Onkologie, Universitätskrankenhaus-Eppendorf, Hamburg

5. Med. Klinik III, Universitärsklinik. Ulm

6. Zentrum für Pharmkalogie und Toxikologie, Medizinische Hochschule Hannover

7. Senckenbergisches Zentrum der Parhologie, Universirätsklinik, Frankfurt/Main, Germany

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.3109/10428199909145712

Reference35 articles.

1. National cancer institute sponsored study of classifications of non-hodgkin's lymphomas. Summary and description of a working formulation for clinical usage

2. The Natural History of Initially Untreated Low-Grade Non-Hodgkin's Lymphomas

3. Cladribine (2-chlorodeoxyadenosine)

4. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin;Leukemia Research;2016-05

2. Initial therapy of mantle cell lymphoma;Therapeutic Advances in Hematology;2011-07-22

3. Older and New Formulations of Cladribine: Pharmacology and Clinical Efficacy in Hematological Malignancies;Frontiers in Anti-Cancer Drug Discovery;2011-03-26

4. Should there be a standard therapy for mantle cell lymphoma?;Future Oncology;2011-02

5. Beyond hairy cell: the activity of cladribine in other hematologic malignancies;Blood;2010-10-21